NEULANDLAB vs PGHL: Stock Comparison
Neuland Laboratories Limited vs Procter & Gamble Health Limited
Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings
Neuland Laboratories Limited is the larger company by market capitalisation. Neuland Laboratories Limited shows faster revenue growth, while Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Neuland Laboratories Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NEULANDLAB | PGHL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NEULANDLAB | PGHL |
|---|---|---|
| Live Price | ₹18,461 | ₹6,742 |
| Day Change | -2.3% | -0.55% |
| Volume | 15,039 | 4,674 |
| 52-Week High | ₹20,089 | ₹6,975 |
| 52-Week Low | ₹11,500 | ₹4,707 |
| Distance from 52W High | -8.1% | -3.34% |
Valuation
| Metric | NEULANDLAB | PGHL |
|---|---|---|
| Market Cap | ₹23,702 Cr | ₹11,172 Cr |
| P/E Ratio | 66.58x | 34.28x |
| P/B Ratio | 12.93x | 21.36x |
| EPS | ₹293.13 | ₹196.64 |
| Book Value | ₹1,460.02 | ₹316.01 |
| Dividend Yield | 0.06% | 2.34% |
Growth
| Metric | NEULANDLAB | PGHL |
|---|---|---|
| Revenue Growth (TTM YoY) | 136.4% | 19.1% |
| EPS Growth (TTM YoY) | 664.4% | 54.6% |
| Qtr Sales Growth | 136% | 19.1% |
| Qtr Profit Growth | 665% | 54.6% |
Profitability & Leverage
| Metric | NEULANDLAB | PGHL |
|---|---|---|
| ROE | 21.4% | 61.6% |
| ROCE | 26.6% | 83.5% |
| Net Margin | 17.99% | 23.22% |
| Operating Margin | 28.4% | 32.4% |
| Debt to Equity | 0.16x | 0.02x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | NEULANDLAB | PGHL |
|---|---|---|
| Promoter Holding | 32.63% | 0% |
| FII Holding | 20.46%▼ 0.44 pp | 6.33%▲ 0.13 pp |
| DII Holding | 15.84%▲ 1.13 pp | 12.44%▼ 1.23 pp |
| Public Holding | 31.07%▼ 0.69 pp | 29.42%▲ 1.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Neuland Laboratories Limited and Procter & Gamble Health Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.